IV to Oral Switch Policy
Indications for IV Route |
1. Sepsis or severe sepsis 2. Febrile with neutropenia or immunosuppression 3. Specific infection indications e.g. Endocarditis, Meningitis, deep abscesses, Staph aureus bacteraemia 4. Oral route compromised, nil by mouth, reduced absorption, mechanical swallowing disorder, unconscious, no oral formulation available |
Definition of Sepsis |
Life threatening organ dysfunction caused by a dysregulated host response to a new infection – IV therapy should be commenced immediately and reviewed on a daily basis as patient improves. Severity of illness may be guided by NEWS. |
IV to Oral Switch Policy |
|
Patients receiving IV therapy MUST be reviewed for a switch to oral WITHIN THE FIRST 72 HOURS then EVERY 24 HOURS THEREAFTER if the indications listed above are not present and the patient is improving. If IV therapy is still required, de-escalate if possible based on microbiology results. Reason for continuing IV therapy MUST be documented at reach review unless suspected/confirmed diagnosis advocating prolonged IV treatment. |
|
General features indicating oral antibiotics are appropriate:
AND there is an oral formulation or alternative antibiotic available should be switched to oral |
IV Agent/Empirical Regime |
Oral Agent |
Amoxicillin |
Amoxicillin 500mg–1g 8 hourly |
Clarithromycin |
Clarithromycin 500mg 12 hourly |
Co-amoxiclav |
Co-amoxiclav 625mg 8 hourly |
Flucloxacillin |
Flucloxacillin 500mg-1g 6 hourly |
Benzylpenicillin |
Amoxicillin 500mg-1g 8 hourly |
Metronidazole |
Metronidazole 400mg 8 hourly |
Ciprofloxacin 400mg 12 hourly |
Ciprofloxacin 500mg 12 hourly |
Ciprofloxacin 400mg 8 hourly |
Ciprofloxacin 750mg 12 hourly |
Levofloxacin |
Levofloxacin 500mg 12 hourly |
Clindamycin |
Clindamycin 300mg-450mg 6 hourly |
Piperacillin/Tazobactam (Tazocin) |
Co-amoxiclav 625mg 8 hourly (if prior co-amoxiclav use - Co-trimoxazole 960mg 12 hourly AND Metronidazole 400mg PO 8 hourly) |
Meropenem |
Based on available sensitivity results or d/w microbiology |
Amoxicillin+Gentamicin+Metronidazole |
Co-amoxiclav 625mg 8 hourly |
Vancomycin+Gentamicin+Metronidazole |
Co-trimoxazole 960mg 12 hourly AND Metronidazole 400mg PO 8 hourly |
Remember CIPROFLOXACIN, METRONIDAZOLE, CLINDAMYCIN and CLARITHROMYCIN have excellent oral bioavailability so oral is as effective as IV
Potential benefits from IV switch
- Earlier mobilisation and potential discharge of patient
- Reduced risk of infection from vascular access devices (e.g. thrombophlebitis, Staph auerus bacteraemia)
- Reduction in non-infectious adverse events associated with IV access (e.g. extravasation, pain)
- Freeing up of nursing time to manage other aspects of patient care
- Improved use of resources